A Patient-Doctor Bond Forged in Fighting Follicular Lymphoma | Dana-Farber Cancer Institute
Along with his wife, Lorna, one individual has been there for Robert Jenkins nearly every step of the way: his oncologist Eric Jacobsen, MD.
Along with his wife, Lorna, one individual has been there for Robert Jenkins nearly every step of the way: his oncologist Eric Jacobsen, MD.
Advanced urothelial cancer (aUC) is often characterized by rapid symptomatic disease progression, making early disease control of particular importance. Circulating tumor DNA (ctDNA) is a…
An abstract is unavailable.
Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.
Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors. …
During the 50th Annual Meeting of the EBMT, Marcoux presented real-life outcomes of auto-HCT in newly diagnosed patients with multiple myeloma and del(17p).
Professor Axel Behrens Scientific Director of the CRUK Convergence Science Centre and leader of the Cancer Stem Cell Group at The Institute of Cancer Research,…
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant ER-positive, HER2-negative breast cancer.
Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.
This ESMO Webinar Series is available to all healthcare professionals working in Oncology.
Join us for an exciting discussion where expert oncologists in the field of colorectal cancer will deliberate on nuances related to sequencing oral tyrosine …